Market Cap 3.55B
Revenue (ttm) 196.54M
Net Income (ttm) -140.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -71.25%
Debt to Equity Ratio 0.69
Volume 2,218,500
Avg Vol 2,440,498
Day's Range N/A - N/A
Shares Out 122.49M
Stochastic %K 21%
Beta 1.69
Analysts Strong Sell
Price Target $31.62

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 418 5006
Address:
3027 Townsgate Road, Suite 300, Westlake Village, United States
jigjagTwits
jigjagTwits Dec. 12 at 8:49 PM
0 · Reply
Rhody27
Rhody27 Dec. 12 at 5:00 PM
$ARQT a great place to add. It’s in the charts.
0 · Reply
5xStarTrader
5xStarTrader Dec. 12 at 3:16 PM
$ARQT MMs are doing a quick Stop Loss Raid to get cheap shares to cover their naked shorting. But surprise Buy Out News is just too big of a risk for me to trade, bc I’ve already paid my tuition fees…and it still hurts to think about it.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:50 AM
Actionable Trade Alert for $ARQT: Market Context: $ARQT is currently trading at $29.76, near the upper range of its 60-day high of $31.77. The RSI at 64.38 indicates it is approaching overbought territory, suggesting potential for a pullback or consolidation before further upward movement. Directional Bias: The stock shows bullish momentum, supported by the MA30 at $27.52 and MA50 at $24.9, both indicating strong support levels. The price is above these moving averages, reinforcing the bullish trend. Trade Plan: - Suggested Entry: $29.76 - Stop Loss: $27.50 (to limit risk) - Take Profit Targets: 1. Target 1: $31.00 (7.6% ROI) 2. Target 2: $32.50 (9.2% ROI) 3. Target 3: $34.75 (16.7% ROI) This plan aims for a minimum of 17% ROI on the third target while maintaining a reasonable risk-reward ratio. Monitor RSI for potential reversals. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 7:52 PM
$ARQT Current Stock Price: $30.01 Contracts to trade: $30 ARQT Dec 19 2025 Call Entry: $0.75 Exit: $1.02 ROI: 36% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Hottehueh
Hottehueh Dec. 10 at 8:01 AM
$ARQT no presentation at JPM HCC... hhhmm
0 · Reply
RonIsWrong
RonIsWrong Dec. 10 at 5:19 AM
$ARQT short interest drops further
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:52 AM
Actionable Trade Alert for $ARQT: Market Context: $ARQT is currently trading at $29.76, showing a strong upward trend. The RSI at 62.92 indicates bullish momentum but suggests caution as it approaches overbought territory. Directional Bias: The price is well above the 30-day MA of 27.21 and the 50-day MA of 24.48, indicating a strong bullish trend. The recent high of $31.77 suggests potential upside, while the low of $16.57 provides a solid support base. Trade Plan: - Suggested Entry: $29.76 - Stop Loss: $27.00 (approximately 9.2% below entry) - Take Profit Targets: 1. Target 1: $31.00 (approx. 4.1% ROI) 2. Target 2: $32.50 (approx. 5.8% ROI) 3. Target 3: $34.80 (approx. 17% ROI) With the current metrics, $ARQT shows potential for significant gains. Monitor closely for market conditions. https://privateprofiteers.com
0 · Reply
Rhody27
Rhody27 Dec. 9 at 3:41 PM
$ARQT thanks for giving me a chance to add in the 20s.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:41 AM
Actionable Trade Alert for $ARQT: Market Context: $ARQT is currently trading at $31.45, exhibiting strong momentum as indicated by an RSI of 77.73, suggesting it is overbought. However, the price is close to the 60D high of $31.77, indicating potential resistance. Directional Bias: The bullish trend is supported by the MA30 (26.88) and MA50 (24.27) being below the current price, indicating upward momentum. The high-low range shows significant volatility, which could provide opportunities for profit. Trade Plan: - Suggested Entry: $31.45 - Stop Loss: $29.00 (approx. 7.8% below entry) - Take Profit Targets: 1. $33.00 (5% gain) 2. $35.00 (11% gain) 3. $36.75 (17.5% gain) The third target aligns with a potential 17% ROI, making this a compelling trade setup. Monitor RSI for signs of reversal as price approaches targets. https://privateprofiteers.com
0 · Reply
Latest News on ARQT
Arcutis Biotherapeutics: The Earnings Inflection Has Arrived

Dec 8, 2025, 1:01 PM EST - 5 days ago

Arcutis Biotherapeutics: The Earnings Inflection Has Arrived


Why Shares in Arcutis Biotherapeutics Surged Again This Week

Nov 21, 2025, 3:47 AM EST - 23 days ago

Why Shares in Arcutis Biotherapeutics Surged Again This Week


Arcutis to Present at Upcoming Investor Conferences

Oct 27, 2025, 4:00 PM EDT - 6 weeks ago

Arcutis to Present at Upcoming Investor Conferences


Arcutis (ARQT) Q2 Revenue Soars 164%

Aug 7, 2025, 12:07 AM EDT - 4 months ago

Arcutis (ARQT) Q2 Revenue Soars 164%


Arcutis Biotherapeutics: Another Approval Under Their Belt

Jun 25, 2025, 4:43 AM EDT - 6 months ago

Arcutis Biotherapeutics: Another Approval Under Their Belt


Arcutis: Out Of The Woods, Ready For Commercialization

Jun 12, 2025, 11:57 PM EDT - 6 months ago

Arcutis: Out Of The Woods, Ready For Commercialization


Arcutis Announces Chief Financial Officer Transition

Apr 10, 2025, 4:30 PM EDT - 8 months ago

Arcutis Announces Chief Financial Officer Transition


Arcutis and Padagis Agree to Stay Patent Lawsuit

Apr 2, 2025, 1:16 PM EDT - 9 months ago

Arcutis and Padagis Agree to Stay Patent Lawsuit


Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

Mar 25, 2025, 8:16 AM EDT - 9 months ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

TNXP


jigjagTwits
jigjagTwits Dec. 12 at 8:49 PM
0 · Reply
Rhody27
Rhody27 Dec. 12 at 5:00 PM
$ARQT a great place to add. It’s in the charts.
0 · Reply
5xStarTrader
5xStarTrader Dec. 12 at 3:16 PM
$ARQT MMs are doing a quick Stop Loss Raid to get cheap shares to cover their naked shorting. But surprise Buy Out News is just too big of a risk for me to trade, bc I’ve already paid my tuition fees…and it still hurts to think about it.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:50 AM
Actionable Trade Alert for $ARQT: Market Context: $ARQT is currently trading at $29.76, near the upper range of its 60-day high of $31.77. The RSI at 64.38 indicates it is approaching overbought territory, suggesting potential for a pullback or consolidation before further upward movement. Directional Bias: The stock shows bullish momentum, supported by the MA30 at $27.52 and MA50 at $24.9, both indicating strong support levels. The price is above these moving averages, reinforcing the bullish trend. Trade Plan: - Suggested Entry: $29.76 - Stop Loss: $27.50 (to limit risk) - Take Profit Targets: 1. Target 1: $31.00 (7.6% ROI) 2. Target 2: $32.50 (9.2% ROI) 3. Target 3: $34.75 (16.7% ROI) This plan aims for a minimum of 17% ROI on the third target while maintaining a reasonable risk-reward ratio. Monitor RSI for potential reversals. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 7:52 PM
$ARQT Current Stock Price: $30.01 Contracts to trade: $30 ARQT Dec 19 2025 Call Entry: $0.75 Exit: $1.02 ROI: 36% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Hottehueh
Hottehueh Dec. 10 at 8:01 AM
$ARQT no presentation at JPM HCC... hhhmm
0 · Reply
RonIsWrong
RonIsWrong Dec. 10 at 5:19 AM
$ARQT short interest drops further
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:52 AM
Actionable Trade Alert for $ARQT: Market Context: $ARQT is currently trading at $29.76, showing a strong upward trend. The RSI at 62.92 indicates bullish momentum but suggests caution as it approaches overbought territory. Directional Bias: The price is well above the 30-day MA of 27.21 and the 50-day MA of 24.48, indicating a strong bullish trend. The recent high of $31.77 suggests potential upside, while the low of $16.57 provides a solid support base. Trade Plan: - Suggested Entry: $29.76 - Stop Loss: $27.00 (approximately 9.2% below entry) - Take Profit Targets: 1. Target 1: $31.00 (approx. 4.1% ROI) 2. Target 2: $32.50 (approx. 5.8% ROI) 3. Target 3: $34.80 (approx. 17% ROI) With the current metrics, $ARQT shows potential for significant gains. Monitor closely for market conditions. https://privateprofiteers.com
0 · Reply
Rhody27
Rhody27 Dec. 9 at 3:41 PM
$ARQT thanks for giving me a chance to add in the 20s.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:41 AM
Actionable Trade Alert for $ARQT: Market Context: $ARQT is currently trading at $31.45, exhibiting strong momentum as indicated by an RSI of 77.73, suggesting it is overbought. However, the price is close to the 60D high of $31.77, indicating potential resistance. Directional Bias: The bullish trend is supported by the MA30 (26.88) and MA50 (24.27) being below the current price, indicating upward momentum. The high-low range shows significant volatility, which could provide opportunities for profit. Trade Plan: - Suggested Entry: $31.45 - Stop Loss: $29.00 (approx. 7.8% below entry) - Take Profit Targets: 1. $33.00 (5% gain) 2. $35.00 (11% gain) 3. $36.75 (17.5% gain) The third target aligns with a potential 17% ROI, making this a compelling trade setup. Monitor RSI for signs of reversal as price approaches targets. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:40 AM
Actionable Trade Alert for $ARQT: Market Context: $ARQT is currently trading at $31.16, showing strong bullish momentum with an RSI of 83.09, indicating overbought conditions. The stock has recently approached its 60D high of $31.39, suggesting potential resistance at this level. Directional Bias: The bullish trend is supported by the MA30 at $26.14 and MA50 at $23.7, both below the current price, indicating strong upward momentum. The high-low range shows significant volatility, with a 60D low of $16.57, suggesting room for upside. Trade Plan: - Suggested Entry: $31.20 - Stop Loss: $29.50 (1.5 ATR below entry) - Take Profit Targets: 1. $32.50 (4.2% gain) 2. $34.00 (8.7% gain) 3. $36.50 (17.5% gain) This trade plan offers a solid risk-reward ratio with a potential ROI of over 17% on the third target. Monitor closely for price action around the 60D high. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:15 PM
Actionable Trade Alert for $ARQT: Market Context: $ARQT is currently trading at $31.16, showing strong bullish momentum with an RSI of 83.09, indicating overbought conditions. The stock has recently approached its 60D high of $31.39, suggesting potential resistance at this level. Directional Bias: The bullish trend is supported by the MA30 at $26.14 and MA50 at $23.7, both below the current price, indicating strong upward momentum. The high-low range shows significant volatility, with a 60D low of $16.57, suggesting room for upside. Trade Plan: - Suggested Entry: $31.20 - Stop Loss: $29.50 (1.5 ATR below entry) - Take Profit Targets: 1. $32.50 (4.2% gain) 2. $34.00 (8.7% gain) 3. $36.50 (17.5% gain) This trade plan offers a solid risk-reward ratio with a potential ROI of over 17% on the third target. Monitor closely for price action around the 60D high. https://privateprofiteers.com
0 · Reply
GoldmanSlaps
GoldmanSlaps Dec. 5 at 3:17 AM
$ARQT $TERN $ADMA mentioned as well 👌🏼
0 · Reply
RonIsWrong
RonIsWrong Dec. 4 at 7:19 PM
$TERN mentioned ( $ARQT in there as well) These stocks are new additions to Mizuho’s ’Americas Top Picks’ list https://finance.yahoo.com/news/stocks-additions-mizuho-americas-top-125733047.html
0 · Reply
Chasetae
Chasetae Dec. 4 at 7:12 PM
$ARQT heading to $38
0 · Reply
AdiDasRom
AdiDasRom Dec. 4 at 5:22 PM
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 4 at 3:14 AM
Attached is a schedule of revenue multiples of all new/recent comm'l-stage oncology & non-oncology with 1st approvals since 1/1/20 & current market caps between $750MM & $5B ($1B - $5B in non-oncology). Note the peer group averages at the bottom in bold. Oncology continues to trade at meaningfully lower multiples than non. However, one can see via a casual review the oncology peer group had more recent approvals. $AUPH was a head scratcher trading at a high multiple where Lupkynis was approved 1/22/2021. AUPH traded meaningfully lower today when the XBI was otherwise strong. Is AUPH trading down to a market (v premium) multiple? $TARS & $ARQT have more or less the same FY2029 revenue estimate as $SNDX yet SNDX trades at a much lower market cap. $IOVA needs to demonstrate it can scale gross margin but the recent lung cancer data is compelling. Patients with these awful lung cancers will use IOVA's TIL. The brutal, rotten unfortunate truth is there are no better options. In time...
1 · Reply
jacksparo
jacksparo Dec. 3 at 11:22 PM
$CAPR $SLNO $RGC $ARQT I have a full documented history here for every trade I shared with my team.. More to come 📈📈📈! 23 years of trading experience!
3 · Reply
Rhody27
Rhody27 Dec. 2 at 5:25 PM
$ARQT added
0 · Reply
skullcool01
skullcool01 Dec. 1 at 2:54 PM
0 · Reply
anachartanalyst
anachartanalyst Nov. 28 at 8:01 PM
$ARQT https://anachart.com/wp-content/uploads/ana_temp/1764360089_soc-img.jpg
0 · Reply
DARKP00L
DARKP00L Nov. 28 at 3:37 PM
$ARQT 10:11 on Nov. 28 2025 Mizuho Maintains Outperform on Arcutis Biotherapeutics, Raises Price Target to $37 #tradeideas
0 · Reply